Canada’s Michael Smith Genome Sciences Centre (GSC) is seeking a Post-doctoral Fellow to conduct a 12-month, industry-facing, translational research project to validate the commercial potential of a high-throughput platform for the discovery and characterization of therapeutic T cell receptors (TCRs).
Tope-seq, developed by Dr. Robert Holt and his research team, is a patented cell-based assay that allows TCR reactivity to be screened in vitro against T cell antigen libraries expressed in synthetic antigen presenting cells. This allows TCR reactivity to be characterized in both a high-throughput and functionally-relevant manner; a combination of capabilities unmatched by current and emerging technologies. The Tope-seq platform aims to de-risk the development of TCR-based immunotherapies by increasing the likelihood that they achieve success in clinical trials, and ultimately, save lives.
The goal of this objective-based project is to use a series of defined experiments to generate data that will be critical in the further development of the Tope-seq platform, and its translation to a commercial environment.
Project areas: Immunogenomics, T cell biology, engineered cell therapy, and synthetic biology.
Duties and Responsibilities
As a Post-doctoral Fellow on the Tope-seq project, you will report to Dr. Robert Holt and the Tope-seq Team. Your typical duties will include the following:
- Designing cell libraries for high-throughput screening experiments.
- Performing high-throughput T cell receptor profiling screens.
- Characterizing and validating novel discoveries stemming from high-throughput screening studies.
- Reporting research methods and results in meetings.
- Contributing to the scientific advancement of the Tope-seq platform
- Contributing to scientific publications, patents, and funding proposals as needed.
The ideal candidate should possess a PhD degree and recent experience in immunology, genomics, cancer biology, cell biology or a related discipline.
Experience in recombinant DNA technologies and viral gene delivery vectors, mammalian cell culture (including primary T cell culture), flow cytometry/FACS, and cell-based assays (such as ELISPOT) is desired. Familiarity with 2nd and 3rd generation DNA sequencing platforms (including single-cell sequencing platforms) will be an asset.
A strong publication record and a track record of success in objective-based research projects are highly desirable. Due to the translational nature of this research project, an interest or aptitude for technology development and/or commercialization would be a valuable asset.
Please submit a detailed cover letter and resume to email@example.com, using Job Reference PDF-Holt Lab in the subject line of your email.
This posting will remain online until filled.
As per the current Public Health Order, full vaccination against COVID-19 is a condition of employment with PHSA as of October 26, 2021
We believe that equity, diversity and inclusivity are essential for the advancement of human knowledge and science.
We welcome all applicants and provide all employees with equal opportunity for advancement, regardless of race, colour, ancestry, place of origin, political belief, religion, marital status, family status, physical or mental disability, sex, sexual orientation, gender identity or expression, age, conviction of a criminal or summary conviction offence unrelated to their employment.
All qualified candidates are encouraged to apply; however, Canadian citizens and permanent residents will be given priority.
About the GSC
The GSC is a department of the BC Cancer Research Institute and a high-throughput genome sequencing facility. We are leaders in genomics, proteomics and bioinformatics in pursuit of novel treatment strategies for cancers and other diseases.
Among the world’s first genome centres to be established within a cancer clinic, for more than two decades our scientists and innovators have been designing and deploying cutting-edge technologies to benefit health and advance clinical research.
Among the GSC’s most significant accomplishments are the first publication to demonstrate the use of whole-genome sequencing to inform cancer treatment planning, the first published sequence of the SARS coronavirus genome and major contributions to the first physical map of the human genome as part of the Human Genome Project.
By joining the GSC you will become part of an exceptional and diverse team of scientists, clinicians, experts and professionals operating at the leading edge of clinical research. We look for people who share our core values—science, timeliness, respect—to join us on our mission to use genome science for the betterment of health and society.